3B Blackbio DX Reports Flat Financial Performance Amidst Year-on-Year Sales Growth in March 2025

3B Blackbio DX, a small-cap player in the healthcare services industry, has reported its financial results for the quarter ending March 2025. The results indicate a flat financial performance, with notable evaluation changes reflected in its score, which has seen a revision from 26 to -3 over the past three months.
On the positive side, the company has achieved net sales of Rs 77.04 crore, marking a year-on-year growth of 28.72%. This suggests a favorable near-term sales trend, indicating that the company is generating revenue effectively.

Conversely, several metrics reveal challenges for 3B Blackbio. The profit before tax less other income (PBT) has shown a decline, recorded at Rs 7.60 crore, which is the lowest in the last five quarters. Additionally, the operating profit margin has reached its lowest point at 35.20%, indicating a decrease in operational efficiency. The profit after tax (PAT) also reflects a year-on-year decline of 5.3%, while earnings per share (EPS) have hit a low of Rs 9.80 in the same timeframe. Furthermore, a significant portion of the company's income is derived from non-operating activities, raising concerns about sustainability.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.